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Abstract Migraine is a recurrent incapacitating neuro-
vascular disorder characterized by unilateral and throbbing
headaches associated with photophobia, phonophobia,
nausea, and vomiting. Current specific drugs used in the
acute treatment of migraine interact with vascular receptors,
a fact that has raised concerns about their cardiovascular
safety. In the past, α-adrenoceptor agonists (ergotamine,
dihydroergotamine, isometheptene) were used. The last two
decades have witnessed the advent of 5-HT1B/1D receptor
agonists (sumatriptan and second-generation triptans),
which have a well-established efficacy in the acute
treatment of migraine. Moreover, current prophylactic
treatments of migraine include 5-HT2 receptor antagonists,
Ca2+ channel blockers, and β-adrenoceptor antagonists.
Despite the progress in migraine research and in view of its
complex etiology, this disease still remains underdiagnosed,
and available therapies are underused. In this review, we
have discussed pharmacological targets in migraine, with
special emphasis on compounds acting on 5-HT (5-HT1–7),
adrenergic (α1, α2, and β), calcitonin gene-related peptide
(CGRP1 and CGRP2), adenosine (A1, A2, and A3), glutamate
(NMDA, AMPA, kainate, and metabotropic), dopamine,
endothelin, and female hormone (estrogen and progesterone)
receptors. In addition, we have considered some other
targets, including gamma-aminobutyric acid, angiotensin,
bradykinin, histamine, and ionotropic receptors, in relation to
antimigraine therapy. Finally, the cardiovascular safety of
current and prospective antimigraine therapies is touched
upon.
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Introduction
Migraine is a complex paroxysmal disorder affecting a
substantial proportion of the population (Rasmussen et al.
1991), with a 2–3-fold higher prevalence in females than in
males (15–18% vs. 6%; Stewart et al. 1992). Migraine is
characterized by episodes of usually throbbing, unilateral,
and severe headaches, which are in about 15% of patients
preceded by reversible focal neurological (mostly visual)
‘aura’ symptoms that tend to develop gradually over 5 to
20 min and last for less than 60 min (Olesen and Lipton
1994). Migraine attacks may be associated with nausea,
vomiting, sensitivity to light and sounds, or movement and,
without treatment, typically last 4 to 72 h (Ferrari and
Saxena 1993; Olesen and Lipton 1994).
The pathogenesis of migraine headache is not complete-
ly understood, but it is thought to involve three key factors,
namely, (a) the cranial blood vessels, (b) the trigeminal
innervation of these vessels, and (c) the reflex connection
Naunyn-Schmiedeberg’s Arch Pharmacol (2008) 378:371–394
DOI 10.1007/s00210-008-0322-7
S. Mehrotra : S. Gupta :K. Y. Chan : P. R. Saxena :
A. MaassenVanDenBrink (*)
Division of Vascular Pharmacology,
Department of Internal Medicine, Erasmus MC,
University Medical Center Rotterdam,
P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
e-mail: a.vanharen-maassenvandenbrink@erasmusmc.nl
URL: http://www.erasmusmc.nl/farmacologie/
C. M. Villalón :D. Centurión
Departamento de Farmacobiología, Cinvestav-Coapa,
Czda. de los Tenorios 235, Col. Granjas-Coapa, Deleg. Tlalpan,
C.P. 14330 Mexico City, Mexico
of the trigeminovascular system (Fig. 1) in the cranial
parasympathetic outflow (Goadsby et al. 2002a). Although
the brain is insensitive to pain, nociceptive stimuli can be
generated by large cranial and proximal intracranial blood
vessels, as well as by the dura mater. Evidence for
peripheral trigeminal activation in migraine is provided by
the release of calcitonin gene-related peptide (CGRP;
Arulmani et al. 2004; Goadsby and Lance 1990) even
though the mechanism of generation of pain is not clear.
Studies in animals have suggested that the pain may be
caused by a sterile neurogenic inflammatory process in the
dura mater (Moskowitz and Cutrer 1993), but this mecha-
nism has not been clearly established to correlate in humans
(May et al. 1998). The pain may be an amalgamation of an
altered perception—as a result of peripheral and/or central
sensitization of craniovascular input that is not usually
painful (Burstein et al. 2000) and the activation of a feed-
forward neurovascular dilator mechanism that is function-
ally explicit for the first (ophthalmic) division of the
trigeminal nerve (May et al. 2001). Nitric oxide (NO) also
seems to be involved in migraine pathophysiology, and
inhibition of its synthesis may have therapeutic relevance
(Lassen et al. 1998). Cranial vasodilatation during a migraine
attack would lead to an enhanced blood volume following
each cardiac stroke, with a resultant augmentation in
pulsations within the affected blood vessels. The increased
pulsations can then be sensed by “stretch” receptors in the
vascular wall, and the resultant boost in perivascular
(trigeminal) sensory nerve activity provokes headache and
other symptoms (Fig. 1; Saxena and Tfelt-Hansen 2006).
This trigeminal stimulation may also release neuropeptides,
thus reinforcing vasodilatation and perivascular nerve
activity (Moskowitz et al. 1989; Villalón et al. 2002).
Receptor subtypes involved in pharmacological
treatments of migraine
Both basic research and clinical studies provide evidence
for several receptor targets in antimigraine therapy. Several
migraine models, based on vascular and neuronal involve-
ment, show that different receptors could be targeted for the
development of antimigraine compounds (Arulmani et al.
2006; De Vries et al. 1999b). In this context, it should be
emphasized that the currently available migraine models do
not entail all facets of this clinically heterogeneous disorder
but are rather based on some of the symptoms observed in
migraine (e.g., focus on only neuronal or vascular aspects).
Thus, no model that mimics all aspects of a migraine attack
is available yet. An important vascular in vivo model
determines blood flow in porcine carotid arteriovenous
anastomoses (Fig. 2). This model is based on the
observation from Heyck (1969) that the oxygen saturation
difference between the arterial and external jugular venous
blood (OSDA-V) was abnormally small during the headache
phase of migraine, being consistent with (a) dilatation of
carotid arteriovenous anastomoses, (b) the facial paleness
and the increase in temporal artery pulsations and swelling
of the frontal vein on the side of the headache (Drummond
and Lance 1983; Drummond and Lance 1984), and (c)
normalization of the decreased OSDA-V after spontaneous
or ergotamine-induced headache relief (Heyck 1969). Other
models utilize electrical stimulation of the trigeminal
ganglion/nerve to study neurogenic dural inflammation,
while the superior sagittal sinus stimulation model takes
into account the transmission of trigeminal nociceptive
input in the brainstem. More recently, the introduction of
integrated models, namely electrical stimulation of the
Fig. 1 Schematic representation of the pathophysiology of migraine.
The pathophysiologic changes in migraine putatively stem from ion
leakage through channels in the brain stem, leading to a decreased
cerebral blood flow (CBF), possibly owing to cortical spreading
depression and, subsequently, neuropeptide release and dilatation of
cranial extracerebral blood vessels. The increased pulsation in these
blood vessels stimulates the trigeminovascular system, setting in
peripheral and central sensitization and leading to headache and
associated symptoms (nausea, vomiting, phonophonophobia, and/or
photophobia). CTZ: Chemoreceptor trigger zone. Redrawn from
Saxena and Tfelt-Hansen (2006)
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trigeminal ganglion or systemic administration of capsaicin,
has allowed studies on the activation of the trigeminal
system and its effects on the cranial vasculature (for review,
see Arulmani et al. 2006). This review also contains data on
the ability of several drugs to inhibit plasma protein
extravasation (e.g., Weiss et al. 2006), although it should
be kept in mind that extravasation inhibitors, such as CP-
122,288 (Roon et al. 2000), the neurokinin-1 receptor
antagonist lanepitant (Goldstein et al. 2001a; Goldstein et
al. 1997), and the mixed ETA/ETB receptor antagonist
bosentan (May et al. 1996) proved ineffective in the
treatment of migraine. Thus, the relevance of plasma
protein extravasation in migraine is no longer tenable
(Peroutka 2005).
On this basis, the present review focuses on recent
pharmacological advances in the treatment of migraine,
while new therapeutic principles are also presented. The
pharmacological targets that will be discussed seem to be
promising because of their involvement in either reducing
total carotid conductance in porcine or canine migraine
models or because of their effects on trigeminovascular
nociceptive pathways.
5-HT receptors
Serotonin [5-hydroxytryptamine (5-HT)], being present in
high concentrations in enterochromaffin cells of gastroin-
testinal mucosa and blood platelets, was identified and
isolated from the gastrointestinal tract (as enteramine) by
Erspamer and colleagues in Italy (Erspamer 1954) and from
the blood (as serotonin) by Page and colleagues in the
United States (Page 1954). In 1948, the American group
deduced that the vasoconstrictor substance serotonin was
chemically 5-HT (Rapport et al. 1948) and, shortly
afterward, the Italians established that enteramine and 5-
HT were identical (Erspamer and Asero 1952). Since then,
a number of 5-HT receptors (5-HT1–7 and their subtypes)
have been identified (Hoyer et al. 1994; Saxena et al. 1998;
Saxena and Villalón 1990) as being responsible for a wide
host of effects (Villalón and Centurión 2007).
Migraine has been described as a “low 5-HT syndrome”,
suggesting that 5-HT may play an important role in its
pathophysiology and treatment (Anthony and Lance 1989).
In this respect, (a) there is an elevation of urinary excretion
of 5-hydroxyindole acetic acid, the major metabolite of 5-
HT, during migraine attacks (Curran et al. 1965); (b)
platelet 5-HT levels were found to drop rapidly during the
onset of a migraine attack (Anthony et al. 1967); (c)
reserpine, which depletes 5-HT (and noradrenaline), pre-
cipitates migraine attacks (Carroll and Hilton 1974); and (d)
intravenous injection of 5-HT reduces headache intensity in
migraineurs (Anthony et al. 1967; Kimball et al. 1960).
5-HT1 receptor subtypes
The 5-HT1 receptor class comprises five different receptor
subtypes, which share 41–63% overall sequence identity
and couple preferentially to Gi/Go to inhibit cAMP
formation (Lesch and Lerer 1991). One of these, the 5-
ht1E receptor, is given a lower-case appellation to denote
that, although gene products encoding putative receptors
have been identified, no functional role has yet been found.
A number of well-defined selective agonists and antag-
onists are available to delineate 5-HT1A receptors. The
5-HT1A agonist buspirone was reported to have a prophy-
lactic effect in migraine with anxiety disorder, which was
not secondary to its anxiolytic effect (Lee et al. 2005).
Further lines of evidence support the hypothesis that
migraine without aura is associated with a relative
hypersensitivity of central 5-HT1A receptors. This is of
relevance given the role of the 5-HT1A receptor in
controlling raphe 5-HT neuronal tone and the possible
association between migraine, anxiety, and depression
(Cassidy et al. 2003). Furthermore, most antimigraine drugs
display high affinity for 5-HT1A and/or 5-HT2 receptor
subtypes in human brain (Peroutka 1988). For example,
tertatolol, which is a β-adrenoceptor antagonist with 5-
HT1A receptor agonist property, decreased porcine carotid
blood flow and conductance, indicating active arteriove-
nous anastomotic constriction. It has therefore been
suggested that tertatolol may prove effective in the
treatment of migraine (Saxena et al. 1992). However,
antimigraine efficacy cannot be explained by drug inter-
Fig. 2 A schematic representation of a vascular bed containing an
arteriovenous anastomosis (AVA), which is a precapillary communi-
cation between artery and veins. When AVAs are dilated, as proposed
to be the case during migraine (Heyck 1969), arterial blood flow will
be shunted to the venous side
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actions with a single 5-HT receptor subtype (Peroutka
1988) and, most importantly, several lines of evidence
argue against 5-HT1A receptor involvement in the constric-
tion of porcine arteriovenous anastomoses, namely, (a)
ipsapirone, a selective 5-HT1A receptor partial agonist, did
not induce carotid vasoconstriction (Bom et al. 1988); (b)
indorenate, another 5-HT1A receptor agonist, induced
porcine carotid vasoconstriction, but metergoline, a drug
with higher affinity for 5-HT1A, 5-HT1B, and 5-HT1D
receptors, failed to significantly antagonize the responses
to indorenate, thus concluding that the effect of indorenate
was not due to its agonist action on 5-HT1A receptors
(Villalón et al. 1990). Therefore, it appears that 5-HT1A
receptors do not mediate vasoconstriction in the porcine
carotid model and the vascular effects mediated by 5-HT1A
receptors seem to be rather limited (if any), while the role
of central activation of 5-HT1A receptors in migraine
remains speculative.
The unambiguous differentiation of 5-HT1B and 5-HT1D
receptor-mediated effects was hampered by the close
pharmacological identity of these receptors. However, two
antagonists can pharmacologically discriminate between
these receptor subtypes, namely, BRL15572 with a 60-
fold selectivity for 5-HT1D over 5-HT1B receptors and
SB224289 with a 75-fold selectivity for 5-HT1B over 5-
HT1D receptors (Price et al. 1997). 5-HT1B/1D receptor
agonists induce selective carotid vasoconstriction (Saxena
et al. 1998). The 5-HT1B receptor is primarily involved in
sumatriptan-induced contractions of human cranial, as well
as certain peripheral blood vessels, as illustrated by the
observation that vasoconstriction induced by 5-carboxami-
dotryptamine and sumatriptan is antagonized by SB224289,
but not by BRL15572 (van den Broek et al. 2002; Villalón
and Centurión 2007; Wackenfors et al. 2005). Moreover, 5-
HT1D and 5-HT1F receptors induce presynaptic inhibition
of the trigeminovascular inflammatory responses implicated
in migraine (Cutrer et al. 1997b; Villalón et al. 2002).
Selective agonists at 5-HT1D (PNU 142633, McCall et al.
2002) and 5-HT1F (LY334370, Phebus et al. 1997) receptors
inhibit the trigeminovascular system without inducing
vasoconstriction. In addition, a central mechanism of action
in blocking the transmission of nociceptive impulses within
the trigeminal nucleus caudalis may contribute to the
antimigraine effect of LY334370 (Shepheard et al. 1999).
Nevertheless, PNU-142633 proved to be ineffective in the
acute treatment of migraine (Gómez-Mancilla et al. 2001),
while LY334370 did show some efficacy in high doses that
may have interacted with 5-HT1B receptors (Goldstein et al.
2001b; Villalón et al. 2002).
There is a high correlation between the potency of
various 5-HT1 receptor agonists in the guinea-pig dural
plasma protein extravasation assay and their 5-HT1F
receptor binding affinity (Ramadan et al. 2003). However,
as previously pointed out, the relevance of plasma protein
extravasation in migraine is no longer tenable (Peroutka
2005). Also, 5-HT1F receptors are located on glutamate-
containing neurons, and their activation might inhibit
glutamate release (Ma 2001), which may be relevant to its
antimigraine action (Martínez et al. 1993). Indeed, most
triptans show high pKi values for 5-HT1F receptors (De
Vries et al. 1999a; Goadsby and Classey 2003). Thus,
although the clinical efficacy of 5-HT1F receptor agonists
has not yet unequivocally been demonstrated, some
preclinical experiments and clinical observations argue in
favor of the potential effectiveness of selective 5-HT1F
agonists in migraine.
Since second-generation triptans may be more brain
penetrant than sumatriptan (Millson et al. 2000), the
relevance of central effects of the triptans should be
considered. Although the second-generation triptans have
not proven more efficacious than sumatriptan (Saxena and
Tfelt-Hansen 2006), they do inhibit trigeminovascular input
to the nucleus tractus solitarius via activation of 5-HT1B/1D
receptors (Hoskin et al. 2004). In addition, inhibitory
actions of 5-HT1B, 5-HT1D and 5-HT1F receptors in the
trigeminocervical complex of the cat have been docu-
mented, and 5-HT1B receptor-mediated inhibition is the
most potent of the three in terms of inhibition of
trigeminovascular nociceptive traffic (Goadsby and Classey
2003). Thus, the 5-HT1B receptor subtype is highly
explored in the drug development for migraine, and the
present drugs for the acute treatment of migraine (namely
triptans) potently stimulate 5-HT1B receptors.
A major disadvantage of triptans is the threat of coronary
vasoconstriction (MaassenVanDenBrink et al. 1998), im-
plying that these drugs should not be administered to
patients with coronary or cerebrovascular disease (Dodick
et al. 2004; Tepper 2001).
5-HT2 receptor subtypes
The 5-HT2 receptor class comprises three receptor subtypes
(i.e., 5-HT2A, 5-HT2B, and 5-HT2C), which exhibit 46–50%
overall sequence identity and couple preferentially to
Gq/G11 to increase the hydrolysis of inositol phosphates
elevating cytosolic [Ca2+] (Shih et al. 1991). The anatom-
ical distribution and physiological function of these three
receptors appear to be discrete. The 5-HT2B and 5-HT2C
receptors display a higher affinity for 5-HT than the 5-HT2A
subtype. Although antagonists for each of these receptors
are now available, only BW723C86 is known as a selective
5-HT2B receptor agonist. This agonist elicits hypertensive
(rather than hypotensive) responses in vagosympathectom-
ized rats (Centurión et al. 2004).
Decreased 5-HT concentrations, as well as an upregula-
tion of 5-HT2 receptors in platelets, have been observed in
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patients with chronic headache, which may be caused by
abuse of analgesic substances (Sarchielli et al. 1999).
Involvement of the 5-HT2 receptor in migraine is suggested
by the 5-HT2 receptor antagonist methysergide, which is
also a partial agonist at 5-HT1 receptors, and is used for
migraine prophylaxis in severe cases where other preventive
drugs are not effective (Silberstein 1998). The 5-HT2A/2C
receptor genes have been studied as candidate genes for
migraine (Buchwalder et al. 1996), but no mutations in the
deduced amino acid sequence of either receptor in the
sample of migraineurs was observed. Thus, the authors
concluded that DNA-based mutations in the 5-HT2A and 5-
HT2C receptors are not generally involved in the pathogen-
esis of migraine. In contrast, Erdal et al. (2001) reported that
the T102C polymorphism of the 5-HT2A receptor gene is
related to migraine with aura. Since the sample size used in
this study was small, the role of the 5-HT2A receptor in the
pathophysiology of migraine or the aura should be consid-
ered with caution.
Concerning the 5-HT2C receptor, alternative splicing
events yield non-functional isoforms of the 5-HT2C recep-
tor, and as many as seven functional isoforms of the 5-
HT2C receptor are produced by adenine deaminase editing
of the receptor messenger RNA (mRNA). Although these
receptor isoforms show no gross differences in their
operational characteristics, they are differentially distributed
throughout central and peripheral tissues. The purpose of
these isoforms remains speculative, but they may be
important in determining cell differences in receptor
desensitization, cell-surface distribution, and/or the traffick-
ing of agonist responses through different effector path-
ways. Thus, there is a need to explore the functions of these
isoforms, which might serve as new targets for future
antimigraine drugs.
Activation of the 5-HT2A receptor leads to an enhance-
ment of NO production in the trigeminovascular pathway.
This NO production may trigger migraine attacks by
inducing cerebral vasodilation and sensitization of the
perivascular nociceptors and central nociceptive neurons
in the trigeminovascular system. Thus, the upregulation of
this pronociceptive receptor can increase headache attacks
and may contribute to the development of chronic daily
headache (Srikiatkhachorn et al. 2002). Also, 5-HT2B
receptors, located on endothelial cells of meningeal blood
vessels, may trigger migraine headache via the formation of
NO. Indeed, 5-HT2B receptor stimulation relaxes the
porcine cerebral artery via the release of NO (Schmuck et
al. 1996). However, if 5-HT2B receptor antagonists are used
in migraine patients, this might lead to coronary side effects
as inhibition of NO production may also induce coronary
vasoconstriction. Indeed, 5-HT2B receptor mRNA has been
demonstrated in human coronary artery (Ishida et al. 1999),
and activation of 5-HT2B receptors in human coronary
artery induces NO release (Ishida et al. 1998). Selective 5-
HT2B receptor antagonists have been described (Forbes et
al. 1995; Johnson et al. 2003) and proven efficacious in
blocking plasma protein extravasation (Johnson et al.
2003). In addition, 8′-hydroxy-dihydroergotamine, the
major metabolite of the antimigraine drug dihydroergota-
mine, may induce a persistent desensitization of 5-HT2B
receptors, which may contribute to its therapeutic efficacy
(Schaerlinger et al. 2003). The study of 5-HT2B receptor
blockade in migraine prophylaxis is awaited to substantiate
the presumed hypersensitivity of these receptors in mi-
graine and, hence, their suspected role in the initiation of
the neurogenic inflammatory response (Cohen et al. 1996;
Fozard and Kalkman 1994; Kalkman 1994; Schmuck et al.
1996).
5-HT3, 5-HT4, 5-ht5A/5B, 5-HT6, and 5-HT7 receptors
The 5-HT3 receptor is unique among existing 5-HT
receptors in being the only member to belong to the
ligand-gated cation channel super-family of receptors
(Hoyer 1990; Hoyer et al. 1994). It appears to be located
exclusively in neuronal tissue, where it mediates fast
depolarization. The receptors are expressed in the central
nervous system, as well as in the periphery, where 5-HT3
receptors are found on autonomic neurons and on neurons
of the sensory and enteric nervous system (Barnes and
Sharp 1999). Although the 5-HT4, 5-HT6, and 5-HT7
receptors all couple preferentially to Gs and promote cAMP
formation, they are classified as distinct receptor classes
because they exhibit <40% overall sequence identity with
other 5-HT receptors (Hoyer et al. 1994). The 5-ht5
receptors include two subtypes, namely, (a) the 5-ht5A
subtype, which is preferentially coupled to the Gi/G0 family
causing adenylyl cyclase inhibition (Francken et al. 1998;
Hurley et al. 1998); (it could also be coupled to inwardly
rectifying potassium channels); and (b) the 5-ht5B subtype,
the transductional system of which is unknown (see
Thomas 2006).
5-HT receptor diversity is increased by the existence of
isoforms produced by post-translational modifications.
Alternative splicing events yield four functional variants
of the 5-HT4 receptor, i.e., 5-HT4(a)–5-HT4(d) (Medhurst et
al. 2001; Pindon et al. 2002), and four functional variants of
the 5-HT7 receptor, i.e., 5-HT7(a)–5-HT7(d) (Krobert and
Levy 2002). The purpose of these isoforms remains
speculative, but they may be important in determining cell
differences in receptor desensitization, cell-surface distri-
bution, or the trafficking of agonist responses through
different effector pathways.
The receptor types mentioned above are not much
explored for the development of antimigraine compounds.
However, some studies have assessed their role in the
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carotid circulation. In one such study, intravenously
administered 5-HT was found to be a vasodilator in vivo
in the cat dural circulation, and the authors showed that the
dilation is not mediated by 5-HT1, 5-HT2, 5-HT4, or 5-HT7
receptors but primarily mediated by a vagal reflex, initiated
via 5-HT3 receptor activation, and brought about by an
increase in parasympathetic tone to the middle meningeal
artery as part of the Von Bezold–Jarisch reflex (Lambert et
al. 2004). Based on the hypothesis that 5-HT3 receptor
antagonists might well inhibit neurogenic dural inflamma-
tion, 5-HT3 receptor antagonists have been assessed for the
treatment of migraine but were unfortunately found to be
ineffective (Ferrari 1991). This lack of effectiveness could
possibly be explained by their complex, bell-shaped, dose–
response relationship, but further trials with adjusted doses
were prevented by their alleged toxicity upon chronic
administration (Ferrari 1991). A clinical indication of 5-
HT3 receptor antagonists is the prevention of emesis
(Hasler 1999). Indeed, control of migraine-associated
nausea and vomiting is often achieved with the benzamide
dopamine D2 receptor antagonist metoclopramide (Dahlöf
and Hargreaves 1998), which also has 5-HT3 receptor
antagonist activity and reproducibly stimulates gastric
motility to increase the availability of orally administered
drugs and is thus used in the treatment of migraine (Dahlöf
and Hargreaves 1998).
There is evidence to suggest that 5-HT7 receptors may
play a role in central nervous system disorders, including
anxiety and cognitive disturbances and also migraine,
probably via both peripheral and central mechanisms
(Thomas and Hagan 2004). Indeed, mRNA of 5-HT7
receptors is present in trigeminal ganglia (Terrón et al.
2001). Since dilatation of cranial blood vessels has been
proposed to play an important role in the pathogenesis of a
migraine attack (Villalón et al. 2002), 5-HT7 receptor
antagonists could well be effective as prophylactic anti-
migraine agents (Terrón et al. 2001). A number of 5-HT7
receptor-selective antagonists, including SB-269970A, SB-
258741, and SB-656104A, have been developed (Pouzet
2002; Thomas and Hagan 2004) but, obviously, clinical
trials are needed to accept or reject their proposed
mechanism of action.
Adrenoceptors
The endogenous catecholamines noradrenaline and adren-
aline, which are released upon activation of the sympathetic
nervous system, play an essential role in the regulation of a
host of physiological responses. Several decades ago,
adrenoceptors were introduced to explain the difference in
actions of noradrenaline and adrenaline (see Hein and
Kobilka 1995). Adrenoceptors are found in nearly all
peripheral tissues and on many neuronal populations within
the central nervous system. Both noradrenaline and adren-
aline play important roles in the control of blood pressure,
myocardial contractile rate and force, airway reactivity, and
a variety of metabolic and central nervous system functions
(Hoffman 2001). Agonists and antagonists interacting with
adrenoceptors have proven useful in the treatment of a
variety of diseases, including hypertension, angina pectoris,
congestive heart failure, asthma, depression, benign pros-
tatic hypertrophy, and glaucoma (Hoffman 2001).
Adrenoceptors can be divided into two major types, the
α- and β-adrenoceptors (Bylund et al. 1994), which can be
further subdivided into several subtypes based on molecular
and pharmacological characteristics, although species
orthologs of some adrenoceptor subtypes have been
identified (Bylund et al. 1995). α1-Adrenoceptors mediate
their actions through stimulation of inositol phosphate
release (Michelotti et al. 2000), while β-adrenoceptors
stimulate (Stiles et al. 1984) and α2-adrenoceptors inhibit
(Limbird 1988) adenylyl cyclase.
α1A- α1B-, and α1D-adrenoceptor subtypes
Cloning has identified three α1-adrenoceptor subtypes. The
α1B-adrenoceptor from the DDT cell line (hamster smooth
muscle) was cloned first (Cotecchia et al. 1988), followed by
the α1A subtype (Ford et al. 1994; Hieble et al. 1995). A
third α1-adrenoceptor was cloned from rat cortex and
designated as the α1A-adrenoceptor (Lomasney et al. 1991).
However, an identical recombinant rat α1-adrenoceptor
subtype was independently identified by Perez et al. (1991)
and denoted the α1D-adrenoceptor. A fourth α1-adrenoceptor
subtype has been postulated and is designated as α1L based
on its low affinity for prazosin (Oshita et al. 1991).
α1-Adrenoceptors are G-protein-coupled receptors and
mediate their responses via a Gq/11 mechanism (Michelotti et
al. 2000). This involves activation of phospholipase C-
dependent hydrolysis of phosphatidyl 4,5-biphosphate gener-
ating inositol 1,4,5 -trisphosphate (IP3), which acts on the IP3
receptor in the endoplasmic reticulum to release stored Ca2+
and diacylglycerol that (together with Ca2+) can activate
protein kinase C. Production of these second messengers
activates both voltage-dependent and voltage-independent
Ca2+ -channels, leading to smooth muscle contraction in both
vascular and non-vascular tissues (e.g., prostate, vas deferens,
and heart).
In line with the findings suggesting that carotid
arteriovenous anastomoses dilate and could play an
important role in the pathogenesis of migraine (Heyck
1969), it is reasonable to assume that compounds that
induce a cranioselective vasoconstriction may have poten-
tial therapeutic use in the treatment of migraine (Willems et
al. 2003). The α1A-adrenoceptor is the main subtype of α1-
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adrenoceptors regulating systemic vascular resistance and
blood pressure (Docherty 1998; Vargas and Gorman
1995). In view of its widespread distribution, it is rather
unlikely that a selective α1A-adrenoceptor agonist would
be useful in the treatment of migraine. Considering this
standpoint, the α1B-adrenoceptor is a motivating target for
future antimigraine drugs, especially when considering
that this receptor does not seem to be much involved in the
constriction of the systemic vasculature (Piascik et al.
1997; Vargas and Gorman 1995), and, predominantly, α1A-,
but not α1B- (or α1D-), adrenoceptors mediate the hyper-
tensive effect induced by intravenous administration of
phenylephrine in anesthetized pigs. Figure 3 (left panel)
depicts the involvement of α1-adrenoceptor subtypes in the
carotid vasculature (Willems et al. 2001b). In addition,
studies in mice have provided several clues to help elucidate
subtype-specific physiological functions, for instance, α1A-
and α1D-adrenoceptor subtypes play an important role in the
regulation of blood pressure (Tanoue et al. 2003). Thus,
these subtypes should not be explored for the development
of novel antimigraine drugs, although such subtype-selective
antagonists might be desirable antihypertensive agents.
Therefore, a selective α1B-adrenoceptor agonist could have
advantages over the currently available acute antimigraine
drugs, which all constrict the human isolated coronary artery
(MaassenVanDenBrink et al. 1998; MaassenVanDenBrink et
al. 2000).
Using a closed cranial window model, the rat dural
vasodilatation in response to electrical stimulation is not
affected by pretreatment with an α1-adrenoceptor agonist
(phenylephrine) or its antagonist (corynanthine; Akerman et
al. 2001). Although these results suggest that the adrenergic
system does not play a significant role in neurogenic dural
vasodilatation, the porcine studies mentioned above do
suggest that α-adrenoceptor agonists should still be
considered for the development of potential antimigraine
drugs. Moreover, studies on human subjects suggest that
migraineurs have sympathetic hypofunction (Boccuni et al.
1989; Peroutka 2004). Accordingly, drugs targeting on
subtypes of α1-adrenoceptors, which lack systemic vaso-
constriction, could hold a promising future in antimigraine
therapy.
α2A, α2B, and α2C-adrenoceptor subtypes
Evidence for the existence of α2-adrenoceptor subtypes has
come from binding and functional studies in various tissues
and cell lines and, more recently, from cells transfected with
the cDNA for the receptors (Bylund 1992). On the basis of
these studies, three genetic and four pharmacologically
distinct α2-adrenoceptor subtypes have been defined. The
α2A-adrenoceptor subtype, for which prazosin has a
relatively low affinity and oxymetazoline a relatively high
affinity (Bylund 1988), has been cloned from humans
(Kobilka et al. 1987). The second subtype, the α2B-
adrenoceptor, has been identified in neonatal rat lung and
in NG108 cells (Bylund et al. 1988). This subtype has a
relatively high affinity for prazosin and a low affinity for
oxymetazoline (Weinshank et al. 1990). A third subtype,
the α2C-adrenoceptor, has been identified in an opossum
kidney cell line and cloned from human kidney (Murphy
and Bylund 1988; Regan et al. 1988). Although this
subtype has a relatively high affinity for prazosin and a
low affinity for oxymetazoline, it is pharmacologically
distinct from the α2B subtype (Blaxall et al. 1991). A fourth
pharmacological subtype, the α2D, has been identified in
the rat salivary gland (Michel et al. 1989) and in the bovine
pineal gland (Simonneaux et al. 1991) and has been cloned
from the rat (Lanier et al. 1991). On the basis of the
predicted amino acid sequence, the α2D is a species
orthologue of the human α2A subtype, and thus, it is not
considered to be a separate subtype.
The role of these subtypes as potential targets in the
treatment of migraine has been elucidated in porcine and
canine migraine models. Studies on these models showed
that the canine carotid vascular responses to the α2-
adrenoceptor agonist BHT933 were markedly attenuated
by the α2A-adrenoceptor antagonist BRL44408 or the α2C-
adrenoceptor antagonist MK912 (given either alone or in
combination) but remained unaffected after administration
of the α2B-adrenoceptor antagonist imiloxan. Figure 3
(right panel) illustrates the effect of α2-adrenoceptor
Fig. 3 The effect of α1 (phenylephrine)- and α2 (BHT933)-
adrenoceptor agonists inducing vasoconstriction in the canine external
carotid circulation. Animals were pretreated with the α1-adrenoceptor
antagonists 5-methylurapidil (5MU) and BMY 7378 (BMY) or the α2-
adrenoceptor antagonists BRL44408 (BRL) and MK-912 (MK;
Willems et al. 2001a). *, P<0.05 vs. corresponding dose of agonist
in control curve. **, P<0.05 vs. corresponding dose of agonist after
administration of the first antagonist (i.e. BMY 7378 in the left panel
and BRL44408 in the right panel)
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subtypes in the canine carotid vascular bed (Willems et al.
2001a). Similarly, the carotid vasoconstrictor responses
produced by BHT933 in anesthetized pigs were markedly
attenuated by MK912, while the other antagonists were
ineffective (Willems et al. 2003). These results suggest that
mainly α2C-adrenoceptors mediate vasoconstriction in the
carotid circulation of both species (Willems et al. 2002). We
also demonstrated the functional role, as well as the mRNA
of α2C-adrenoceptors, in the porcine isolated meningeal
artery (Mehrotra et al. 2006). Thus, α2C-adrenoceptor
agonists could be useful targets for the development of
potential antimigraine drugs.
Additionally, other studies have shown the lack of
response to clonidine in menstrual migraine, where the
authors speculated about a postsynaptic α2-adrenoceptor
hyposensitivity during the premenstrual period (Facchinetti
et al. 1989). Indeed, we have demonstrated an increased
function of α2-adrenoceptors in ovariectomized rats sug-
gesting that, if this phenomenon also occurs in humans, it
may contribute to the decreased frequency of migraine after
menopause (Mehrotra et al. 2007). Furthermore, it has
recently been reported that α2-adrenoceptors produce a
specific NMDA-induced nociception in the trigeminal
region in male and ovariectomized female rats, while this
response was absent in female rats with circulating estrogen
(Nag and Mokha 2006). Thus, a transient vulnerability of
the neuroendocrine/neurovegetative systems in female
migraine patients could be a factor that facilitates the
precipitation of migraine attacks. Clearly, more studies are
required in this direction and could possibly open new
avenues for the pharmaceutical companies to develop
subtype-selective agonists.
β-Adrenoceptors
In 1967, two subtypes of the β-adrenoceptor were
identified by comparing the rank orders of agonist potency
(Ahlquist 1967; Lands et al. 1967). The β1-adrenoceptor,
the dominant receptor in heart and adipose tissue, was
equally sensitive to noradrenaline and adrenaline, whereas
the β2-adrenoceptor, responsible for relaxation of vascular,
uterine, and airway smooth muscle, was much less sensitive
to noradrenaline in comparison with adrenaline (Lands et
al. 1967). Highly selective antagonists for both β1- and β2-
adrenoceptors have been developed, as well as many potent
and selective β2-adrenoceptor agonists. Subsequently, it has
become apparent that not all β-adrenoceptor-mediated
responses can be classified as either β1 or β2, suggesting
the existence of at least the β3-adrenoceptor subtype (Arch
et al. 1984; Bond and Clarke 1988). The β3-adrenoceptor is
insensitive to the commonly used β-antagonists and has
often been referred to as the ‘atypical’ β-adrenoceptor. It is
unlikely that all of the atypical β-adrenoceptor responses
observed have characteristics consistent with those of the
β3-adrenoceptor and, hence, the possibility of additional
subtypes cannot be excluded. Pharmacological evidence has
been accumulated for a fourth β-adrenoceptor localized in
cardiac tissues of various species (Kaumann 1997). This β4-
adrenoceptor is activated with a low potency by noradren-
aline and adrenaline and is blocked by β-adrenoceptor
antagonists, such as bupranolol and CGP20712A (Galitzky
et al. 1997; Sarsero et al. 1998).
Among all β-adrenoceptor blockers, propranolol and, to a
lesser extent, metoprolol, underwent the most extensive
clinical testing for cardiac disease and served in many clinical
trials as reference drugs when β-adrenoceptor blockers were
compared with non-adrenergic drugs (Limmroth and Michel
2001). The efficacy of β-adrenoceptor blockers for the
prophylaxis of migraine was discovered by chance when
patients with migraine, who received β-adrenoceptor
blockers for cardiac disorders, observed a significant
reduction of migraine frequency (Rabkin et al. 1966). On
the other hand, it still remains controversial whether all β-
adrenoceptor blockers have a prophylactic efficacy in
migraine or it is limited to individual members of this drug
class with specific characteristics. β-blockade results in
(a) inhibition of noradrenaline release by blocking pre-
junctiononal β-adrenoceptors (Lakhlani et al. 1994) and
(b) a delayed reduction in tyrosine hydroxylase activity,
the rate-limiting step in noradrenaline synthesis, in the
superior cervical ganglia (Hieble 2000). It is also suggested
that lipophilicity (penetration into the central nervous
system), membrane-stabilizing effects and intrinsic sympa-
thomimetic activity are relevant for antimigraine efficacy.
Moreover, some β-adrenoceptor blockers have high affinity
for certain 5-HT receptor subtypes (Cruickshank and
Prichard 1994). The β1-adrenoceptor affinity appears to play
a major role in determining prophylactic efficacy since
nonselective agents such as propranolol, moderately β1-
selective agents such as metoprolol, and highly β1-selective
drugs such as bisoprolol (van de Ven et al. 1997; Würz et al.
1991) all are effective prophylactics. Thus, concomitant
blockade of β2-adrenoceptors does not appear to be required
for effective migraine prophylaxis. While propranolol,
metoprolol, oxprenolol, and alprenolol are very lipophilic
and, hence, penetrate well into the central nervous system,
atenolol, nadolol, and practolol are only slightly or not at all
lipophilic (Cruickshank and Prichard 1994). As several
members of the latter group, including atenolol (Forssman
et al. 1983; Johannsson et al. 1987) and nadolol (Freitag and
Diamond 1984; Sudilovsky et al. 1987), have been reported
to be effective in the prophylactic treatment of migraine
attacks, high lipophilicity and, hence, penetration into the
central nervous system does not appear to be required for
prophylactic efficacy. The reports on prophylactic efficacy of
atenolol (Forssman et al. 1983; Johannsson et al. 1987),
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nadolol (Freitag and Diamond 1984; Sudilovsky et al. 1987),
and timolol (Stellar et al. 1984; Tfelt-Hansen et al. 1984)
suggest that membrane-stabilizing effects are not required to
reduce the frequency of migraine attacks. Finally, it should
be noted that only β-adrenoceptor antagonists without partial
agonist activity are effective in the prophylactic treatment of
migraine (Tfelt-Hansen and Rolan 2006).
CGRP receptors
CGRP is one of the most potent endogenous vasodilators. On
the basis of pharmacological criteria, it is known that CGRP
may act mainly on CGRP1 and CGRP2 receptors (Arulmani
et al. 2004), with h-αCGRP8–37 being a 10-fold more potent
antagonist at CGRP1 receptors than at CGRP2 receptors
(Quirion et al. 1992). While CGRP1 receptors are widely
distributed, CGRP2 receptors have only been described in rat
vas deferens and are more sensitive to the linear agonists
[ethylamide-Cys2,7]h-αCGRP and [acetimidomethyl-Cys2,7]
h-αCGRP than CGRP1 receptors (Dumont et al. 1997).
CGRP1 receptors consist of at least three main different
entities, namely, the calcitonin receptor-like receptor (CLR),
receptor-activity-modifying protein-1 (RAMP-1; McLatchie
et al. 1998), and receptor component protein (RCP; Luebke
et al. 1996; Poyner et al. 2002), whereas CGRP2 receptors
have not yet been molecularly characterized. The molecular
components of CGRP1 receptors that have been demonstrat-
ed in the human meningeal artery include CLR, RCP, and
RAMPs 1, 2, and 3 (Durham 2004; Gupta et al. 2006a;
Jansen-Olesen et al. 2003; Oliver et al. 2002). The results
from our laboratory also advocate the presence of CGRP1
receptors in human meningeal (Gupta et al. 2006a) and
coronary (Gupta et al. 2006b) arteries, while in human distal
coronary artery, there seems to be an additional population of
CGRP receptors not complying with the current classifica-
tion of CGRP1 or CGRP2 receptors (Gupta et al. 2006b).
Furthermore, RAMP-1 seems to be functionally rate limiting
for CGRP receptor activity in the trigeminal ganglion,
suggesting that the increase in function of RAMP-1 might
sensitize some individuals to the actions of CGRP in
migraine (Zhang et al. 2007).
In the recent past, there has been an upsurge in CGRP
research and its notable role in migraine pathophysiology.
CGRP immunoreactive fibers originating in the trigeminal
ganglion innervate cranial blood vessels (Uddman et al.
1985). In animals, stimulation of these sensory nerve fibers
has been shown to cause antidromic release of CGRP and
subsequent vasodilatation in the cranial vasculature (Brain
and Grant 2004; Goadsby et al. 1988). Indeed, CGRP
induces a concentration-dependent relaxation in the middle
cerebral artery in a pressurized arteriography model in rats
only when CGRP was administered abluminally. This
suggests that CGRP-mediated vasodilatation is not mediated
by luminally situated receptors but by receptors on the
smooth muscle cells (Petersen et al. 2005a). Moreover, CGRP
receptor antagonists could also act at a central level, as
exemplified by the fact that it modulates nociceptive
trigeminovascular transmission in the cat (Storer et al.
2004a). Hence, inhibition of CGRP release or antagonism
of CGRP receptors could be a viable therapeutic target for
the pharmacological treatment of migraine (Edvinsson
2004).
Further evidence for a role of CGRP in migraine is
provided by the observations that plasma concentrations of
CGRP, but not of other neuropeptides, in the jugular venous
blood are elevated during the headache phase of migraine
(Edvinsson and Goadsby 1994). Furthermore, in migraine
patients, (a) a strong correlation was found between
plasma CGRP concentrations and migraine headache as
the changes in plasma CGRP levels during migraine attacks
significantly correlated with the headache intensity
(Durham 2004; Iovino et al. 2004; Petersen et al. 2005b);
(b) infusion of CGRP produced a migraine-like headache
(Olesen et al. 2004); and (c) baseline CGRP levels were
increased in migraineurs (Fusayasu et al. 2007).
An important breakthrough in the field of CGRP was the
development of the potent and selective CGRP receptor
antagonist olcegepant (BIBN4096BS; Doods et al. 2000).
In in vivo animal models of migraine, olcegepant attenuated
the vasodilation induced by trigeminal stimulation and
capsaicin-induced carotid arteriovenous anastomotic dilata-
tion (Doods et al. 2000; Edvinsson 2004; Kapoor et al.
2003; Petersen et al. 2005b). In addition, olcegepant has
been shown to prevent CGRP-induced headache and
extracerebral vasodilatation (Petersen et al. 2005b) but does
not significantly affect the induced cerebral hemodynamic
changes (Fig. 4). Data from a clinical proof-of-concept
study demonstrate the effectiveness of olcegepant in the
acute treatment of migraine, with the response rate being
similar to oral triptans (Olesen et al. 2004). These lines of
evidence are in accordance with recent findings in a larger,
ramdomized controlled trial of the orally available CGRP
receptor antagonist MK-0974 (Ho et al. 2008), which,
similar to olcegepant, is a potent antagonist of the human
CGRP receptors (Salvatore et al. 2008). Since olcegepant
does not induce vasoconstriction per se, this CGRP receptor
antagonist has been argued to be safer than triptans,
particularly in migraineurs suffering from cardiovascular
pathologies. However, it must be highlighted that CGRP
has a protective function during coronary ischemia, which
was blocked by olcegepant in a Langendorff rat heart model
(Chai et al. 2006). Thus, if these findings hold for humans
as well, CGRP receptor antagonists, like the triptans, may
also be contraindicated in patients with coronary artery
disease.
Naunyn-Schmiedeberg’s Arch Pharmacol (2008) 378:371–394 379
Adenosine receptors
Adenosine is present in all body fluids and it differs from
ATP in that it is not stored by and released from secretory
vesicles. Rather, it exists freely in the cytosol of all cells
and is transported in and out of cells mainly via membrane
transporters. Adenosine in tissues comes partly from
membrane transporters and partly from released ATP or
ADP. Adenosine produces many pharmacological effects,
both in the periphery and in the central nervous system
(Brundege and Dunwiddie 1997). One of its functions
appears to be as a protective agent when tissues are
threatened (e.g., cardiac or cerebral ischemia), based on
its ability to inhibit cell functions and thus minimize the
metabolic requirements of the cells. Under less extreme
conditions, variations in the adenosine release may play a
role in controlling blood flow, matching it to the metabolic
needs of the tissue. Adenosine acts on four well-defined G-
protein-coupled receptors. These receptors are denoted as
adenosine receptors but may also be called P1-receptors to
distinguish them from the receptors for nucleotides, which
belong either to the family of transmitter-gated ion channels
(P2X receptors) or the family of G-protein-coupled receptors
(P2Y receptors). The P1 receptors are classified as four
adenosine receptors, called A1, A2A, A2B, and A3, which
have been cloned from several mammalian species,
including humans (Fredholm et al. 2001). Several studies
on knockout and transgenic mice have shown various roles
of each of these subtypes (IUPHAR 2006).
Whereas adenosine A2 receptor gene variation may
contribute to the pathogenesis of migraine with aura
(Hohoff et al. 2007), adenosine A1 receptor agonists such
as GR79236 seem to have a role in inhibiting trigeminal
nociception in humans (Giffin et al. 2003) and could
therefore be useful in the treatment of migraine. In the cat,
GR79236 induced neuronal inhibition without concomitant
vasoconstriction (Goadsby et al. 2002b). In the rat, the
adenosine A1 receptor antagonist DPCPX prevented the
inhibitory effect of GR79236 on neurogenic vasodilatation,
which was primarily mediated by prejunctional A1-receptors
(Honey et al. 2002). GR79236 has no effect on resting
meningeal artery diameter in rats (Honey et al. 2002)
and inhibits forskolin-stimulated CGRP release in rats
(Carruthers et al. 2001). Likewise, in cats, GR79236 has
been shown to significantly reduce the CGRP levels in the
external jugular vein (Fig. 5; Goadsby et al. 2002b).
However, in pigs, GR79236 has no effect on capsaicin-
induced CGRP release (Arulmani et al. 2005), and,
consequently, the authors concluded that the antimigraine
potential of GR79236 could be due to its postjunctional
effects (carotid vasoconstriction) rather than to prejunctional
inhibition of trigeminal CGRP release. Thus, although the
underlying mechanisms have not yet completely been
elucidated, there is evidence that adenosine receptor agonists
may be beneficial in the treatment of migraine via neuronal or
vascular effects. In view of the latter effects, adenosine receptor
stimulationmay lead to delayed Ca2+ uptake and could, hence,
contribute to a delayed cardioprotective effect of adenosine
(Ghelardoni et al. 2005), which may have implications for the
cardiovascular safety of these compounds.
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Fig. 5 Cranial CGRP release in anesthetized cats under basal
conditions (control), after stimulation of the superior sagittal sinus
(SSS), and after SSS in animals pretreated with the adenosine A1
receptor agonist GR79236 (30 μg/kg, i.v.). #P<0.05 compared to
control; *P<0.05 compared to SSS (Goadsby et al. 2002b)
Fig. 4 Diameter of superficial temporal (squares) and radial (circles)
arteries after treatment with placebo (open symbols) or olcegepant
(2.5 mg, closed symbols) measured by high-frequency ultrasound in
ten healthy volunteers in double-blind, placebo-controlled crossover
study. Asterisks denote significant difference (P<0.05) between
pretreatment with placebo and olcegepant on human α-calcitonin
gene-related peptide (h-aCGRP)-induced vasodilatation (Petersen et
al. 2005b)
380 Naunyn-Schmiedeberg’s Arch Pharmacol (2008) 378:371–394
ATP and its breakdown products adenosine monophos-
phate and adenosine are potent dilatators of cerebral blood
vessels. During ischemia, ATP binding to metabotropic
P2Y-receptors on endothelial cells results in release of NO,
which diffuses to the vascular smooth muscles causing
vasodilatation and hyperemia (Burnstock 2000). Addition-
ally, ATP contributes to pain in migraine by activating
nociceptive terminals of primary afferents located near the
basal cerebral and dural vasculature where P2X-receptor
subtypes, which are sensitive to the lowered extracellular
pH, are suggested to be responsible for excitatory effects on
trigeminal sensory neurons (Cook and McCleskey 1997;
Cook et al. 1997; Hamilton and McMahon 2000). Further-
more, Zimmermann et al. (2002) showed that ATP (a) has a
poor, if any, direct CGRP releasing effect on trigeminal
nerve endings in the dura; (b) may contribute to pain in
migraine by facilitating nociceptor responses to tissue
acidosis via the P2Y-receptor; and (c) may involve release
of endogenous prostaglandins. Recently, P2X3-receptors
have been shown to be upregulated in trigeminal neurons
by CGRP; thus, this mechanism might contribute to pain
sensitization and could represent a model of neuronal
plasticity in response to a migraine mediator (Fabbretti et
al. 2006). Therefore, further research in migraine should
focus on the role of P2-receptors, their subtypes, and how
they are implicated in migraine pathophysiology.
Glutamate receptors
Glutamate and its receptors play a major excitatory role in
the brain (for references, see Cyr et al. 2001). The effects of
glutamate on brain excitability are mediated via the
ionotropic NMDA, AMPA, and kainate receptors, as well
as the metabotropic glutamate receptor (Sang et al. 2004).
Glutamate-like immunoreactivity has been seen in the
dental pulp neurons that project to the trigeminal nucleus
caudalis (TNC) in the rat (Clements et al. 1991). Indeed, all
the major receptor classes of glutamate have been identified
in the superficial lamina of the rat trigeminal nucleus
caudalis (Tallaksen-Greene et al. 1992). Stimulation of the
trigeminal nerve increases extracellular glutamate, which in
turn excites TNC neurons (Quartu et al. 2002; Sahara et al.
1997). As glutamate receptors are co-localized in neurons
in the trigeminal ganglion with 5-HT1B, 5-HT1D, and 5-
HT1F receptors, 5-HT1 autoreceptors may presynaptically
inhibit the release of glutamate (Ma 2001). Since glutamate
may be involved in the cortical hyperexcitability typical of
migraine (Goadsby 2005), the above ionotropic glutamate
receptors are being studied as potential antimigraine targets
(Sang et al. 2004).
The NMDA receptor antagonist MK-801 and the AMPA
receptor antagonist GYKI-52466 are effective in blocking
trigeminovascular nociception in the trigeminocervical
nucleus (Classey et al. 2001; Goadsby and Classey 2000;
Storer and Goadsby 1999). In addition, the NMDA receptor
antagonists MK-801 and AP-5 reduce capsaicin-evoked
CGRP release (Garry et al. 2000), pointing to potential
vascular effects of glutamate receptor antagonists (Jackson
and Hargreaves 1999).
Blockade of both NMDA and non-NMDA ionotropic
receptors reduces the c-fos protein expression in the
trigeminal nucleus caudalis after intracisternal capsaicin
injection (Mitsikostas et al. 1999; Mitsikostas et al. 1998).
Indeed, the mixed AMPA/kainate receptor antagonist
LY293558 has been shown to be effective in the acute
treatment of migraine (Sang et al. 2004). Also lamotrigine,
a sodium channel blocker with antiglutamatergic actions,
seemed highly effective in reducing migraine aura and
migraine attacks in a controlled open study (Lampl et al.
2005). Similarly, the anticonvulsant topiramate is effective
in migraine prophylaxis (Brandes et al. 2004; Diener et al.
2004; Silberstein et al. 2004). This effect may be mediated
by blockade on voltage-activated Na+ and Ca2+ channels
and/or blockade of AMPA and kainate receptors.
Interestingly, patients taking nitroglycerin for reducing
the risk of developing cardiac ischemia or infarction often
complain of headache. In these patients, infusion of
ketamine, a NMDA receptor antagonist, in concurrence
with fentanyl for postoperative pain relief, was proposed to
be effective against this NO-induced headache (Roffey et
al. 2001). Moreover, in a small open-label study, intranasal
ketamine was reported to reproducibly reduce the severity
and duration of the neurologic deficits due to the aura in
five out of 11 patients with familial hemiplegic migraine
(FHM; Kaube et al. 2000). Remarkably, in a subpopulation
of patients with FHM, a mutation in the gene encoding for
the glutamate transporter, which decreases the expression of
the transporter, has been reported (Jen et al. 2005). This
mutation may increase the levels of glutamate, leading to
cortical hyperexcitability. On the other hand, there is ample
evidence, both from basic and clinical studies, that
decreased concentrations of ionized magnesium (Mg2+)
are associated with a decreased threshold for triggering a
migraine attack (Mody et al. 1987; Ramadan et al. 1989;
Sarchielli et al. 1992). Decreased Mg2+ concentrations also
can activate NMDA receptors and, thus, can increase
neuronal excitability. In agreement with this hypothesis, the
infusion of Mg2+ provided sustained headache relief (Bigal
et al. 2002), and oral Mg2+ has been demonstrated to be an
effective prophylactic in menstrual migraine (Facchinetti et
al. 1991). Thus, glutamate receptor modulators seem to be of
benefit in migraine treatment; indeed, the NMDA receptor
antagonist memantine and the NR2B subunit containing
antagonist, CP-101,606, decreased spreading depression
(Peeters et al. 2007), a potentially important factor in
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migraine pathophysiology. However, stronger basic and
clinical evidence for the delineation of their exact role in
the pathogenesis of migraine, as well as their cardiovascular
safety, is awaited with great interest.
Dopamine receptors
Dopamine is a catecholamine that serves as a neurotrans-
mitter in the brain (Carlsson et al. 1957; Carlsson et al.
1958). Dopamine is synthesized from tyrosine, which is
sequentially converted to L-dihydroxyphenylalanine (L-
DOPA) by the enzyme tyrosine hydroxylase. L-DOPA is
then converted to dopamine in cytoplasm by the enzyme
DOPA decarboxylase (Hoffman 2001). The distribution of
dopamine in the brain is highly non-uniform and more
restricted than the distribution of noradrenaline. A large
proportion of the dopamine content in the brain is found in
the corpus striatum and the limbic system. Dopaminergic
neurons lack dopamine β-hydroxylase and thus do not
produce noradrenaline. Pharmacological evidence suggests
that dopaminergic neurons have a role in the production of
nausea and vomiting. Dopamine exerts its action by five
receptor subtypes that have been cloned. The D1-like
receptors (D1 and D5) are closely related G-protein-coupled
receptors (Gsα-protein subunit) that stimulate adenylyl
cyclase activity. In contrast, D2-like receptors (D2, D3, and
D4) are coupled to Giα-protein subunits with a similar
pharmacology and inhibit the formation of cAMP. Their
isoforms are encoded by homologous genes displaying
several introns (Alexander et al. 2007).
The vascular and nervous systems, both likely to be
involved in migraine pathophysiology, both respond to
dopamine (Akerman and Goadsby 2007). Dopamine and
related receptor agonists have vasoactive effects on blood
vessels in vitro and in vivo, inducing vasoconstriction or
vasodilatation, depending on the species, vascular bed, and
dose (Hughes et al. 1986; Smith et al. 1990; Takenaka et al.
1993; Villalón et al. 2003; Yu et al. 2002).
The dopamine agonist lisuride is useful in the prophy-
laxis of migraine (Del Bene et al. 1983; Herrmann et al.
1978; Somerville and Herrmann 1978), although its exact
mechanism of action is still to be unraveled. As lisuride is
an extremely potent 5-HT2B receptor antagonist (Hofmann
et al. 2006), it is reasonable to assume that the antimigraine
action of this drug could be mediated, at least partly, via
blockade of 5-HT2B receptors. More recently, haloperidol,
which blocks D1, D2, 5-HT2, H1, and α2-adrenergic
receptors in the brain, was reported to be effective in the
acute treatment of migraine in a randomized, double-blind,
placebo-controlled study, although the majority of patients
suffered from side effects (Honkaniemi et al. 2006).
Dopamine causes vasoconstriction in rat dural arteries, but
this effect is most likely mediated by α2-adrenoceptors and
not dopamine receptors (Akerman and Goadsby 2005). In
addition, dopamine-containing neurons may play a role in
modulating trigeminovascular nociception; when dopamine
was administered microiontophoretically (and not intrave-
nously), it inhibited the activation of trigeminocervical
neurons in response to middle meningeal artery stimulation
(Bergerot et al. 2007). Furthermore, pharmacological studies
with dopaminergic agonists like apomorphine suggest that
migraineurs may present a dopaminergic hypersensitivity,
even interictally (Blin et al. 1991; Cerbo et al. 1997;
Peroutka 1997). The increased density of D5, D3, and D4
receptors in blood lymphocytes in migraine patients may
reflect the dopaminergic hypersensitivity and may thus
represent a relatively simple and reliable peripheral marker
of altered dopaminergic function (Barbanti et al. 1996;
Barbanti et al. 2000). In addition, high platelet levels of
dopamine have been observed in migraineurs (D’Andrea et
al. 2006). Several association studies on D2-like receptors
and migraine with or without aura have been reported, but
with contradictory results (Maude et al. 2001; Mochi et al.
2003; Peroutka et al. 1998; Peroutka et al. 1997). Thus, it
appears that if dopamine and its receptors are at all involved
in the pathophysiology of migraine, the exact mechanism of
action still remains unclear.
Endothelin receptors
Endothelin was identified by Yanagisawa et al. (1988), who
isolated, analyzed, and cloned the gene of this potent
vasoconstrictor in a very short space of time. There are
three isoforms of endothelin, namely, ET-1, ET-2, and ET-3,
which are variably distributed and derived from separate
genes. ET-1 is the main isoform and is produced in the
cardiovascular system, ET-2 is mainly produced in the
kidney and intestines, whereas ET-3 is predominant in
the central nervous system. ET-1 mediates its action
through binding to specific G-protein-coupled receptors,
ETA and ETB. ETA receptors are mainly present in vascular
smooth muscle and mediate vasoconstriction and cell
proliferation, whereas activation of ETB receptors present
in endothelial cells causes NO-induced vasodilatation and
prostacyclin release (Attina et al. 2005).
Increased peripheral plasma levels of ET-1 (Hasselblatt
et al. 1999; Kallela et al. 1998), even several hours after a
migraine attack (Farkkila et al. 1992), led to suggest the
involvement of ET-1 in migraine pathogenesis. Evidence of
association of migraine and the ETA receptor gene
polymorphism (ETA-231 A/G) in a French population-
based study (Tzourio et al. 2001) has added a new
candidate gene for migraine. In rats, ET-1 is one of the
most potent inducers of Leão’s spreading depression
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(Dreier et al. 2002), but Goadsby et al. (1996) reported no
effect of endothelin receptor antagonists in preventing
spreading depression in cats. The major setback for the
hypothesis of involvement of ET-1 in migraine pathogen-
esis comes from a study showing the lack of efficacy of the
mixed ETA/ETB receptor antagonist bosentan in migraine
(May et al. 1996). However, the ETA and ETB receptors are
likely to mediate opposite effects, and it is feasible that
more selective endothelin receptor antagonists may be
effective in the acute treatment of migraine. In addition,
the efficacy of endothelin receptor antagonists in migraine
prophylaxis is still to be evaluated.
Female sex hormone (estrogen and progesterone)
receptors
The female sex steroid hormones estrogen and progesterone
regulate numerous biological functions via two main mech-
anisms, which are mediated by genomic (transcription-
dependent) and/or non-genomic (transcription independent)
pathways (Kelly and Levin 2001; Lau 2002; Orshal and
Khalil 2004). Ovarian steroids are lipophilic in nature, and
their low molecular weight allows them to cross the blood–
brain barrier by passive diffusion (Aloisi 2003). In the central
nervous system, these hormones induce a wide array of
physiological effects.
The genomic actions of sex steroids encompass two
different receptors (ERα and ERβ) for estrogens (Enmark
and Gustafsson 1999), as well as two receptors (PR-A and
PR-B) for progesterone (Kastner et al. 1990). While female
sex steroids do not seem to be involved in the pathogenesis
of migraine per se, they may modulate several mediators
and/or receptor systems via both genomic and non-genomic
mechanisms. These actions may be perpetuated at the central
nervous system, as well as at the peripheral (neuro) vascular
level (Gupta et al. 2007). The receptors of both estrogen and
progesterone alter receptor expression and release, as well as
synthesis of various neurotransmitters and hormones. For
example, CGRP, a facilitator of pain transmission and a
potent vasodilator (Bennett et al. 2000; Powell et al. 2000),
neuropeptide Y, a regulator of inflammation and central
nociception (Silva et al. 2002), as well as the neuro-
transmitters glutamate (Zhang and Bhavnani 2005), and 5-
HT (Smith et al. 2004) have been reported to be genomically
modulated by sex steroids. Remarkably, progesterone can act
in a synergistic, antagonistic, or neutral manner compared to
the effects of estrogens (Attali et al. 1997; Becker and
Rudick 1999; Dluzen and Ramírez 1989; Fernández-Ruíz et
al. 1990; Hernández et al. 1991). The receptors and
mechanisms involved in their non-genomic action are not
yet completely deciphered (Gupta et al. 2007; Martin and
Behbehani 2006).
Primary evidence for the involvement of female sex
hormones in migraine pathogenesis comes from the facts
that the prevalence of migraine is 2–3-fold higher in women
than in men (Lipton et al. 2001; Stewart et al. 1992) and
that reproductive milestones such as menarche, pregnancy,
and menopause are associated with changes in migraine
frequency and/or severity (Silberstein 2000). Interestingly,
individuals with a polymorphism at G594 (exon 8) of the
estrogen receptor-1 (ESR1) gene are twice more likely to
suffer from migraine than those with the wild-type gene
(Colson et al. 2004). Similarly, individuals carrying the
PROGINS inserts of the progesterone receptor gene
polymorphism are twice as likely to suffer from migraine
than control subjects (Colson et al. 2005). It is worth
mentioning that the estrogen receptor polymorphism
increases its expression (Colson et al. 2004), whereas the
progesterone receptor polymorphism negatively impacts its
expression. Furthermore, it is interesting that the PROGINS
allele of the progesterone receptor acts synergistically with
the 594A allele of ESR1 to increase the risk of migraine by
3.2 times (Colson et al. 2005).
Hormonal interventions have been explored as a prophy-
lactic treatment of menses-related migraine or migraine
experienced during the pill-free period. Oral estrogens
(Calhoun 2004; Somerville 1975) and percutaneous estradiol
showed benefit during perimenstrual treatment, which was
balanced when delayed by estrogen withdrawal, triggering
post-dosing migraine immediately after the gel was stopped
(MacGregor et al. 2006a). Furthermore, rising levels of
estrogen appear to offer some protection against migraine
(MacGregor et al. 2006b). Thus, estrogen patches have been
utilized to prevent the rapid decline of estrogen levels during
the menstrual cycle (MacGregor 2006; MacGregor et al.
2006a; MacGregor et al. 2006b; MacGregor and Hackshaw
2002; Magos et al. 1983), which is thought to be the main
trigger of migraine in these patients (MacGregor 2006).
These studies have reported mixed results ranging from no
improvement to 80% improvement and are also based on a
relatively limited number of patients (n=11–38). Taken
collectively, there is a strong evidence for the involvement
of female sex steroids, especially that of estrogens, but the
therapeutic role of estrogen supplements for conditions like
menstrual migraine remains to be established.
Miscellaneous receptors and ion channels
GABA receptors
Gamma-aminobutyric acid (GABA) is the major inhibitory
neurotransmitter in the mammalian central nervous system.
GABA induces inhibitory hyperpolarization effects in neurons,
although excitatory responses can be found at certain loci in
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embryonic and postnatal life, as well as in adult hippocampal
pyramidal neurons. GABA exerts its effects through GABAA
and GABAB receptors. GABAA receptors are ligand-gated
ion channels sensitive to bicuculline (Barnard et al. 1998),
whereas GABAB receptors are G-protein-coupled receptors
insensitive to bicuculline and stimulated by baclofen (Bowery
et al. 2002). Also, GABAC receptors, which are insensitive to
bicuculline, benzodiazepines, or barbiturates, have been
described, but these receptors are not yet completely
characterized (Barnard et al. 1998; Spedding et al. 2002).
GABA may be involved in the pathophysiology of
migraine since (a) increased GABA concentrations in
cerebrospinal fluid have been reported during a migraine
attack (Welch et al. 1975); (b) increased platelet levels of
GABA have been observed in patients with tension-type
headache (Kowa et al. 1992), although it should be kept in
mind that the pathophysiology of migraine and tension-type
headache are obviously different; and (c) sodium valproate
and muscimol dose dependently inhibit plasma protein
extravasation induced by electrical stimulation of the
trigeminal ganglion, and these effects are blocked by the
GABAA receptor antagonist bicuculline (Lee et al. 1995). It
thus appears that selective agonists of GABAA receptors
could be clinically effective in the treatment of migraine.
Consistent with this view, several agonists at GABA
receptors have been used as prophylactic antimigraine
drugs. In this context, valproate (Cutrer et al. 1997a;
Shaygannejad et al. 2006), baclofen in a small open study
(Hering-Hanit 1999), and gabapentin (Di Trapani et al.
2000) may prevent migraine attacks, while valproate has
also been suggested to be effective in the acute treatment of
migraine in another small open trial (Mathew et al. 2000).
Despite the above clinical evidence, it should be kept in mind
that not all of the aforementioned compounds are selective in
their action at GABA receptors, and the mechanisms
involved in their antimigraine effect remain unclear. Several
studies have shown that valproate inhibits GABA transami-
nase and activates glutamic acid decarboxylase to increase
brain GABA levels. Moreover, GABA may suppress the
hyperexcitability observed in aura (Palmer et al. 2000),
probably by blocking Na+ and/or Ca2+ channels (Cutrer
2001). Recently, it has been suggested that GABAA receptors
can inhibit trigeminovascular nociceptive transmission in the
cat (Storer et al. 2004b). These findings suggest that the
development of more selective GABAA receptor agonists
may be fruitful in the treatment of migraine.
Angiotensin receptors
Angiotensin II is an octapeptide derived from angiotensino-
gen. Angiotensinogen, released from the liver, is converted to
angiotensin I by renin released by the kidney. Then,
angiotensin I is converted by angiotensin converting enzyme
(ACE), mainly located in the lungs, to angiotensin II.
Angiotensin II activates two receptor types, AT1 and AT2.
The AT1 receptor is involved in the regulation of arterial
blood pressure (vasoconstriction), electrolyte balance (anti-
natriuresis), thirst, hormone secretion (aldosterone), and renal
function (De Gasparo et al. 2000). In contrast, AT2 receptors
can produce opposite effects to those by the AT1 receptor,
i.e., natriuresis and vasodilatation (Widdop et al. 2003).
Although the role of angiotensin II in the pathogenesis of
migraine is not established, clinical evidence suggests that
several ACE inhibitors such as lisinopril and enalapril can
be effective in migraine (Bender 1995; Schrader et al.
2001). Moreover, the angiotensin AT1 receptor antagonist
candesartan (Tronvik et al. 2003) also seems to be effective
as prophylactic antimigraine drug, which may be general-
ized to other drugs from the same class as suggested by an
open-label study in 24 patients using olmesartan (Charles et
al. 2006). In addition, genetic studies suggest an association
between ACE gene polymorphisms and migraine (Paterna
et al. 2000). Further, ACE activity in migraine with aura is
reported to be significantly higher than in migraine without
aura and control subjects (Fusayasu et al. 2007). Despite
the above evidence, the role of angiotensin II in the
pathophysiology of migraine should be clarified in animal
models to understand the mechanism(s) of action involved.
This could be useful to rationally develop more selective
antimigraine drugs interacting with the renin–angiotensin
system.
Bradykinin receptors
The nonapeptide bradykinin belongs to the kinin family and
is synthesized by cleavage of high and low molecular
weight kininogens through serine proteases (kininogenases;
Moreau et al. 2005). Plasma and tissue kallikrein are the
two main kininogenases. Once released, bradykinin can
activate two main receptors (B1 and B2), which are G-
protein-coupled and linked to activation of phospholipase C
(Marceau and Regoli 2004). The B1 receptor is generally
induced during inflammation by lipopolysaccharide and
cytokines such as interleukin-1β, interleukin-6, and tumor
necrosis factorα, while the B2 receptor is constitutive and
widely distributed in blood vessels. B1-receptor-mediated
effects include vasodilatation, plasma protein extravasation,
inflammatory pain, activation of leukocyte-endothelial cell
interactions, and leukocyte accumulation.
Bradykinin is involved in inflammatory responses and
locally induces release of NO and PGI2 (prostacyclin) from
the endothelium, as well as substance P and CGRP from
neurones. Although this peptide could be involved in
neurogenic inflammation during a migraine attack (Geppetti
et al. 1990), its precise role in migraine pathophysiology is
not well established. Since B1 receptors are expressed
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following noxious stimuli and mediate vasodilatation and
neurogenic plasma extravasation, B1-receptor antagonists
may be useful as antimigraine drugs. Moreover, several B2-
receptor antagonists have analgesic properties (Moreau et
al. 2005), which could be explained by the capability of
bradykinin to stimulate primary afferent nerves during
inflammation. Thus, both B1- and B2-receptor antagonists
might potentially be useful in the treatment of migraine.
Histamine receptors
Histamine is a monoamine mainly stored in mast cells in
most tissues. Histamine plays an important role on allergic
responses and in the central nervous system as a neuro-
transmitter. The effects of histamine are mediated by four
receptors (H1, H2, H3, and H4). The H1 receptor is
positively coupled to phospholipase C and mediates, among
other effects, smooth muscle contraction, release of NO,
and increased vascular permeability. The H2 receptor
stimulates adenylyl cyclase and produces smooth muscle
relaxation, positive inotropic and chronotropic effects in the
heart, and stimulation of gastric secretion. The H3 and H4
receptors are both G-protein-coupled receptors mediating
inhibition of adenylyl cyclase, but much of their functional
role remains to be determined (IUPHAR 2006).
Clinical evidence has suggested that histamine is
involved in the pathogenesis of migraine. Intravenous
infusion of histamine induces headache, which is blocked
by the H1 receptor antagonist, mepyramine (Lassen et al.
1995). This effect of histamine could be due to activation of
endothelial H1 receptors that release NO (Lassen et al.
1996). Consistent with these views, histamine produces rat
dural vasodilatation, which is sensitive to mepyramine (H1
antagonist), famotidine (H2 antagonist), and L-NAME, an
NO synthase inhibitor (Akerman et al. 2002). In addition,
clinical studies indicate that the histamine metabolite and
H1/2/3 receptor agonist, N-α-methyl-histamine (Hill et al.
1997), can be used as a prophylactic antimigraine drug
(Millán-Guerrero et al. 2006; Millán-Guerrero et al. 2003).
N-α-methyl-histamine can block the plasma protein extra-
vasation induced by electrical trigeminal ganglion stimula-
tion (Matsubara et al. 1992) or by capsaicin in rats and
guinea pigs. Moreover, the selective H3 receptor agonist
(R)-α-methyl-histamine inhibits capsaicin-induced dural
plasma extravasation in the rat (Rouleau et al. 1997). Taken
together, it appears that antagonists at H1/2 receptors or
agonists at H3 receptors could be useful as acute and/or
prophylactic antimigraine drugs.
Ion channels
Recently, knowledge on the role of mutant ion channels in
the pathogenesis of episodic neurological disorders has
emerged (Hanna 2006). Molecular characteristics of genetic
channelopathies have contributed to a better understanding
of episodic diseases such as migraine, where new mutations
in the P/Q-type voltage-gated Ca2+ channel gene CAC-
NA1A, the Na+ /K+-ATPase gene ATP1A2, as well as the
Na+ channel gene SCN1A have been demonstrated in FHM
(for review, see van den Maagdenberg et al. 2007). Ion
concentrations may modulate vascular constriction and
relaxation, as well as cortical excitability. For example,
decreased Mg2+ concentrations are associated with cortical
spreading depression in animals (Mody et al. 1987). Indeed,
there is evidence for low Mg2+ levels in brain during
(Ramadan et al. 1989) and between (Lodi et al. 1997)
migraine attacks. As mentioned above, Ca2+ seems to be
involved in the pathogenesis of migraine as mutations in
P/Q-type Ca2+ channels are related to FHM (Ophoff et al.
1996) and, possibly, also to migraine with and without aura
(Terwindt et al. 2001). Further, L-type Ca2+ channels
modulate the release of CGRP in trigeminal neurons
innervating the cranial vasculature (Akerman et al. 2003).
Ca2+ channel blockers such as verapamil (Ramadan et al.
1997) and flunarizine (Buchanan et al. 2004) are used for
the prophylactic treatment of migraine. However, the
mechanism of action of these Ca2+ channel blockers is yet
poorly understood.
Implications, future directions, and conclusions
Disregarding the limitations of basic research, a multidis-
ciplinary approach encompassing both basic and clinical
observations will inevitably be needed to understand the
role of different receptor systems in migraine. As the
pathophysiology of migraine has not yet been completely
deciphered, experimental models employed in migraine
research are based on only a few symptoms observed in the
clinical situation. Thus, there is a need to integrate several
neuronal and vascular experimental models, as well as
clinical observations in migraine research. To investigate
the involvement of certain receptors in migraine, multiple
agonists and antagonists should be used.
In view of the concern about coronary vasoconstriction
induced by vasoactive antimigraine drugs and stimulated by
the discovery of genetic ion channel abnormalities in
migraine, research has recently focused on the development
of neuronally acting antimigraine drugs. More knowledge
on the mechanism of action of these (prospective) neuro-
nally active antimigraine drugs may substantially contribute
to the (prophylactic) treatment of migraine. On the other
hand, many of these drugs are likely to exert (indirect)
vascular effects as well, which may contribute to the
therapeutic efficacy but also may lead to cardiovascular
side effects.
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In conclusion, the results obtained with various (pre)
clinical models studying the targets mentioned in the
present review, such as CGRP receptor antagonists,
adenosine receptor agonists, and glutamate receptor antag-
onists, are eagerly awaited and will undoubtedly shed
further light on the pathophysiology of migraine.
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